EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies

Bispecific antibody therapeutics can expand the functionality of a conventional monoclonal antibody drug because they can bind multiple antigens. However, their great potential is counterbalanced by the challenges faced in their production. The classic asymmetric bispecific containing an Fc requires...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooke, Heather A., Arndt, Joe, Quan, Chao, Shapiro, Renée I., Wen, Dingyi, Foley, Susan, Vecchi, Malgorzata M., Preyer, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284599/
https://www.ncbi.nlm.nih.gov/pubmed/30215570
http://dx.doi.org/10.1080/19420862.2018.1519631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284599/
https://www.ncbi.nlm.nih.gov/pubmed/30215570
http://dx.doi.org/10.1080/19420862.2018.1519631

Ejemplares similares